| Recommendations—follow-up . | LoE . | Grade . |
|---|---|---|
| Assess the response to therapy at 3, 6, and 12 mo and every 12 mo thereafter | 4 | C |
| Aim for a target TT level of 15–30 nmol/L to achieve optimal response | 4 | C |
| Monitor hematocrit before treatment, at 3–6 mo, 12 mo, and every 12 mo thereafter; decrease dosage, or switch preparation, if hematocrit is >0.54; if hematocrit remains high, consider stopping and reintroduce at lower dose | 4 | C |
| Assess prostate health by PSA assessment and DRE before commencing T replacement therapy followed by PSA at 3–6 mo, 12 mo, and every 12 mo thereafter | 4 | C |
| Assess CV risk before T replacement therapy is initiated and monitor CV risk factors throughout therapy | 1b | A |
| Recommendations—follow-up . | LoE . | Grade . |
|---|---|---|
| Assess the response to therapy at 3, 6, and 12 mo and every 12 mo thereafter | 4 | C |
| Aim for a target TT level of 15–30 nmol/L to achieve optimal response | 4 | C |
| Monitor hematocrit before treatment, at 3–6 mo, 12 mo, and every 12 mo thereafter; decrease dosage, or switch preparation, if hematocrit is >0.54; if hematocrit remains high, consider stopping and reintroduce at lower dose | 4 | C |
| Assess prostate health by PSA assessment and DRE before commencing T replacement therapy followed by PSA at 3–6 mo, 12 mo, and every 12 mo thereafter | 4 | C |
| Assess CV risk before T replacement therapy is initiated and monitor CV risk factors throughout therapy | 1b | A |
| Recommendations—follow-up . | LoE . | Grade . |
|---|---|---|
| Assess the response to therapy at 3, 6, and 12 mo and every 12 mo thereafter | 4 | C |
| Aim for a target TT level of 15–30 nmol/L to achieve optimal response | 4 | C |
| Monitor hematocrit before treatment, at 3–6 mo, 12 mo, and every 12 mo thereafter; decrease dosage, or switch preparation, if hematocrit is >0.54; if hematocrit remains high, consider stopping and reintroduce at lower dose | 4 | C |
| Assess prostate health by PSA assessment and DRE before commencing T replacement therapy followed by PSA at 3–6 mo, 12 mo, and every 12 mo thereafter | 4 | C |
| Assess CV risk before T replacement therapy is initiated and monitor CV risk factors throughout therapy | 1b | A |
| Recommendations—follow-up . | LoE . | Grade . |
|---|---|---|
| Assess the response to therapy at 3, 6, and 12 mo and every 12 mo thereafter | 4 | C |
| Aim for a target TT level of 15–30 nmol/L to achieve optimal response | 4 | C |
| Monitor hematocrit before treatment, at 3–6 mo, 12 mo, and every 12 mo thereafter; decrease dosage, or switch preparation, if hematocrit is >0.54; if hematocrit remains high, consider stopping and reintroduce at lower dose | 4 | C |
| Assess prostate health by PSA assessment and DRE before commencing T replacement therapy followed by PSA at 3–6 mo, 12 mo, and every 12 mo thereafter | 4 | C |
| Assess CV risk before T replacement therapy is initiated and monitor CV risk factors throughout therapy | 1b | A |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
